Jaski B E, Fifer M A, Wright R F, Braunwald E, Colucci W S
J Clin Invest. 1985 Feb;75(2):643-9. doi: 10.1172/JCI111742.
Milrinone is a potent positive inotropic and vascular smooth muscle-relaxing agent in vitro, and therefore, it is not known to what extent each of these actions contributes to the drug's hemodynamic effects in patients with heart failure. In 11 patients with New York Heart Association class III or IV congestive heart failure, incremental intravenous doses of milrinone were administered to determine the dose-response relationships for heart rate, systemic vascular resistance, and inotropic state, the latter measured by peak positive left ventricular derivative of pressure with respect to time (dP/dt). To clarify further the role of a positive inotropic action, the relative effects of milrinone and nitroprusside on left ventricular stroke work and dP/dt were compared in each patient at doses matched to cause equivalent reductions in mean arterial pressure or systemic vascular resistance, indices of left ventricular afterload. Milrinone caused heart rate, stroke volume, and dP/dt to increase, and systemic vascular resistance to decrease in a concentration-related manner. At the two lowest milrinone doses resulting in serum concentrations of 63 +/- 4 and 156 +/- 5 ng/ml, respectively, milrinone caused significant increases in stroke volume and dP/dt, but no changes in systemic vascular resistance or heart rate. At the maximum milrinone dose administered (mean serum concentration, 427 +/- 11 ng/ml), heart rate increased from 92 +/- 4 to 99 +/- 4 bpm (P less than 0.01), mean aortic pressure fell from 82 +/- 3 to 71 +/- 3 mmHg (P less than 0.01), right atrial pressure fell from 15 +/- 2 to 7 +/- 1 mmHg (P less than 0.005), left ventricular end-diastolic pressure fell from 26 +/- 3 to 18 +/- 3 (P less than 0.005), stroke volume index increased from 20 +/- 2 to 30 +/- 2 ml/m2 (P less than 0.005), stroke work index increased from 14 +/- 2 to 21 +/- 2 g X m/m2 (P less than 0.01), and dP/dt increased from 858 +/- 54 to 1,130 +/- 108 mmHg/s (P less than 0.005). When compared with nitroprusside for a matched reduction in mean aortic pressure or systemic vascular resistance, milrinone caused a significantly greater increase in stroke work index at the same or lower left ventricular end-diastolic pressure. Milrinone caused a concentration-related increase in dP/dt (32% increase at maximum milrinone dose), whereas nitroprusside had no effect. These data in patients with severe heart failure indicate that in addition to a vasodilating effect, milrinone exerts a concentration-related positive inotropic action that contributes significantly to the drug's overall hemodynamic effects. The positive inotropic action occurs at drug levels that do not exert significant chronotropic or vasodilator effects.
米力农在体外是一种强效的正性肌力药和血管平滑肌舒张剂,因此,目前尚不清楚这些作用各自在多大程度上对心力衰竭患者的药物血流动力学效应有贡献。在11例纽约心脏病协会III级或IV级充血性心力衰竭患者中,静脉递增给予米力农,以确定心率、全身血管阻力和正性肌力状态的剂量-反应关系,后者通过左心室压力相对于时间的峰值正向导数(dP/dt)来测量。为了进一步阐明正性肌力作用的作用,在每例患者中比较了米力农和硝普钠在使平均动脉压或全身血管阻力(左心室后负荷指标)同等降低的剂量下对左心室每搏功和dP/dt的相对影响。米力农使心率、每搏量和dP/dt增加,并使全身血管阻力以浓度相关的方式降低。在导致血清浓度分别为63±4和156±5 ng/ml的两个最低米力农剂量下,米力农使每搏量和dP/dt显著增加,但全身血管阻力或心率无变化。在给予的最大米力农剂量(平均血清浓度,427±11 ng/ml)时,心率从92±4次/分钟增加到99±4次/分钟(P<0.01),平均主动脉压从82±3 mmHg降至71±3 mmHg(P<0.01),右心房压从15±2 mmHg降至7±1 mmHg(P<0.005),左心室舒张末期压力从26±3 mmHg降至18±3 mmHg(P<0.005),每搏量指数从20±2 ml/m²增加到30±2 ml/m²(P<0.005),每搏功指数从14±2 g·m/m²增加到21±2 g·m/m²(P<0.01),dP/dt从858±54 mmHg/s增加到1130±108 mmHg/s(P<0.005)。当与硝普钠比较使平均主动脉压或全身血管阻力匹配降低时,米力农在相同或更低的左心室舒张末期压力下使每搏功指数显著更大增加。米力农使dP/dt呈浓度相关增加(最大米力农剂量时增加32%),而硝普钠无作用。这些重度心力衰竭患者的数据表明,除了血管舒张作用外,米力农还发挥浓度相关的正性肌力作用,这对药物的整体血流动力学效应有显著贡献。正性肌力作用发生在不产生显著变时性或血管舒张作用的药物水平。